Low baseline platelet count predicts poor response to plerixafor in patients with multiple myeloma undergoing autologous stem cell mobilization

Mohammed Bakeer, Abba C. Zubair, Vivek Roy

Research output: Contribution to journalArticle

Abstract

Background aims: Baseline platelet count has been shown to be a sensitive predictor of autologous peripheral blood progenitor cell collection yield in patients with multiple myeloma mobilized with granulocyte colony-stimulating factor (G-CSF). Patients who mobilize poorly with G-CSF are often treated with plerixafor to enhance mobilization. There are no surrogate markers available to predict response to plerixafor. Methods: We retrospectively analyzed data from 73 patients with multiple myeloma who did not have adequate mobilization with G-CSF alone and were treated with plerixafor as a rescue agent. Results: We found that baseline platelet count directly correlated with peripheral blood CD34+ (PB-CD34+) count after plerixafor treatment (r = 0.36, P < 0.0001) and the number of PB-CD34+ cells collected on the first day of apheresis and inversely correlated with the number of apheresis sessions needed to collect the target number of PB-CD34+ cells (P = 0.0015). Baseline platelet count of 153 000/µL or less was associated with 90% specificity of predicting poor response to plerixafor with a sensitivity of 33%. Conclusions: Baseline platelet count is a good predictor of mobilization response to plerixafor in patients with multiple myeloma.

Original languageEnglish (US)
Pages (from-to)16-20
Number of pages5
JournalCytotherapy
Volume22
Issue number1
DOIs
StatePublished - Jan 2020

Keywords

  • autologous transplant
  • hematopoietic stem cell mobilization
  • platelet count
  • plerixafor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Genetics(clinical)
  • Cell Biology
  • Cancer Research
  • Transplantation

Fingerprint Dive into the research topics of 'Low baseline platelet count predicts poor response to plerixafor in patients with multiple myeloma undergoing autologous stem cell mobilization'. Together they form a unique fingerprint.

  • Cite this